SEARCH

SEARCH BY CITATION

References

  • 1
    Eslam M, Aparcero R, Kawaguchi T, Del Campo JA, Sata M, Khattab MA, Romero-Gomez M. Meta-analysis: insulin resistance and sustained virological response in hepatitis C. Aliment Pharmacol Ther 2011;34:297-305.
  • 2
    Deltenre P, Louvet A, Lemoine M, Mourad A, Fartoux L, Moreno C, et al. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol 2011;55:1187-1194.
  • 3
    Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009;49:739-744.
  • 4
    Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, Diago M, Alonso S, Planas R, Solá R, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008;48:721-727.
  • 5
    Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-848.
  • 6
    Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes, and ageing. Nat Rev Mol Cell Biol 2011;12:21-35.
  • 7
    Del Campo JA, García-Valdecasas M, Rojas L, Rojas Á, Romero-Gómez M. The hepatitis C virus modulates insulin signaling pathway in vitro promoting insulin resistance. PLoS One 2012;7:e47904.
  • 8
    García-Ruiz I, Solís-Muñoz P, Gómez-Izquierdo E, Muñoz-Yagüe MT, Valverde AM, Solís-Herruzo JA. Protein-tyrosine phosphatases are involved in interferon resistance associated with insulin resistance in HepG2 cells and obese mice. J Biol Chem 2012;287:19564-19573.
  • 9
    Romero-Gómez M, Diago M, Andrade RJ, Calleja JL, Salmerón J, Fernández-Rodríguez CM, et al.; Spanish Treatment of Resistance to Insulin in Hepatitis C Genotype 1 Group. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009;50:1702-1708.
  • 10
    Harrison SA, Hamzeh FM, Han J, Pandya PK, Sheikh MY, Vierling JM. Chronic hepatitis C genotype 1 patients with insulin resistance treated with pioglitazone and peginterferon alpha-2a plus ribavirin. Hepatology 2012;56:464-473.
  • 11
    Moucari R, Forestier N, Larrey D, Guyader D, Couzigou P, Benhamou Y, et al. Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut 2010;59:1694-1698.
  • 12
    Lam KD, Bacchetti P, Abbasi F, Ayala CE, Loeb SM, Shah V, et al. Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity. Hepatology 2010;52:38-46.
  • 13
    Younossi Z, Negro F, Serfaty L, Pol S, Diago M, Zeuzem S, et al. The homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. Hepatology 2013;58:1897-1906.
  • 14
    Del Campo JA, Ampuero J, Rojas L, Conde M, Rojas A, Maraver M, et al. Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism. Aliment Pharmacol Ther 2013;37:74-80.
  • 15
    Belperio PS, Hwang EW, Thomas IC, Mole LA, Cheung R, Backus LI. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C. Clin Gastroenterol Hepatol 2013 Mar 21. doi: 10.1016/j.cgh.2013.03.006.
  • 16
    Podevin P, Carpentier A, Pene V, Aoudjehane L, Carriere M, Zaidi S, et al. Production of infectious hepatitis C virus in primary cultures of human adult hepatocytes. Gastroenterology 2010;139:1355-1364.
  • 17
    Grove J, Nielsen S, Zhong J, Bassendine MF, Drummer HE, Balfe P, et al. Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol 2008;82:12020-12029.
  • 18
    Sheridan DA, Bridge SH, Felmlee DJ, Crossey MM, Thomas HC, Taylor-Robinson SD, et al. Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: evidence for an association with interferon sensitivity. J Hepatol 2012;57:32-38.
  • 19
    Sheridan DA, Neely RD, Bassendine MF. Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs). Clin Res Hepatol Gastroenterol 2013;37:10-16.